Finance

Lists
Why is NKTR up 3.07%?
Dive Deeper
NKTR:NASDAQ
Nektar Therapeutics
US$37.26
+3.07%
(+1.11) 1D
US$37.26
0.00% (0.00)
After hours
Closed: ኖቬም 6, 4:00:01 ከሰዓት ጂ ኤም ቲ-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NKTR...
Open
US$36.58
High
US$37.58
Low
US$36.44
Mkt. cap
1.27 ቢ
Avg. vol.
1.31 ሚ
Volume
686.44 ሺ
52-wk high
US$109.00
52-wk low
US$33.40
EPS
-US$6.69
Beta
1.44
Shares outstanding
34.14 ሚ
No. of employees
63
Open
US$36.58
High
US$37.58
Low
US$36.44
Mkt. cap
1.27 ቢ
Avg. vol.
1.31 ሚ
Volume
686.44 ሺ
52-wk high
US$109.00
52-wk low
US$33.40
EPS
-US$6.69
Beta
1.44
Shares outstanding
34.14 ሚ
No. of employees
63
News stories
From web sources and news partners
About Nektar Therapeutics
CEO-
Employees63
Founded1990
Headquartersሳን ፍራንሲስኰ, ካሊፎርኒያ, ዩናይትድ ስቴትስ
SectorHealth Care
IndustryBiotechnology
Websitenektar.com
Analyst ratings
Based on 14 analysts giving stock ratings to NKTR in the past 3 months
Buy
Buy
10
Hold
4
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for NKTR in the last 3 months.
Highest
Current US$37.26
US$192.00 (+415.30%)
Average
US$132.45 (+255.48%)
Lowest
US$50.00 (+34.19%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
US$192.00
+415.3%
10/22/2026
Will Soghikian
Leerink Partners
Buy
Initiated
US$130.00
+248.9%
10/12/2026
Unknown Analyst
Leerink Partners
Buy
Initiated
US$130.00
+248.9%
10/12/2026
Alice Nettleton
UBS
Hold
Initiated
US$53.00
+42.2%
10/11/2026
Julian Harrison
BTIG
Buy
Maintained
US$178.00
+377.7%
10/09/2026
Thomas Deal
Raymond James
Hold
Initiated
-
-
10/08/2026
Unknown Analyst
Raymond James
Hold
Initiated
-
-
10/08/2026
Samantha Semenkow
Citi
Buy
Reiterated
US$151.00
+305.3%
10/05/2026
Unknown Analyst
B. Riley Securities
Buy
Maintained
US$150.00
+302.6%
10/02/2026
Roger Song
Jefferies
Buy
Maintained
US$150.00
+302.6%
10/01/2026
Andy Hsieh
William Blair
Buy
Maintained
-
-
10/01/2026
Arthur He CFA
H.C. Wainwright
Buy
Maintained
US$185.00
+396.5%
10/02/2026
Edward Nash
Canaccord Genuity
Buy
Maintained
US$153.00
+310.6%
09/28/2026
Martin Fan
Wedbush
Hold
Reiterated
US$50.00
+34.2%
09/23/2026
Jessica Fye
J.P. Morgan
Hold
Initiated
US$65.00
+74.4%
08/21/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
08/13/2026
Jay Olson
Oppenheimer
Buy
Maintained
US$140.00
+275.7%
05/08/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
US$150.00
+302.6%
02/23/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ሴፕቴ 2025
ዲሴም 2025
ማርች 2026
ጁን 2026
Revenue
11.79 ሚ
21.81 ሚ
10.86 ሚ
10.13 ሚ
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
27.25 ሚ
29.71 ሚ
35.68 ሚ
39.13 ሚ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
16.07 ሚ
11.18 ሚ
13.44 ሚ
12.76 ሚ
Operating expense
43.32 ሚ
40.90 ሚ
49.12 ሚ
51.89 ሚ
Total operating expenses
43.32 ሚ
40.90 ሚ
49.12 ሚ
51.89 ሚ
Operating income
-31.53 ሚ
-19.09 ሚ
-38.26 ሚ
-41.76 ሚ
Other non operating income
-121.00 ሺ
-44.00 ሺ
-336.00 ሺ
-100.00 ሺ
EBT including unusual items
-35.56 ሚ
-36.05 ሚ
-44.84 ሚ
-40.62 ሚ
EBT excluding unusual items
-35.42 ሚ
-27.47 ሚ
-44.04 ሚ
-40.04 ሚ
Income tax expense
-33.00 ሺ
31.00 ሺ
64.00 ሺ
2.00 ሺ
Effective tax rate
0.09%
-0.09%
-0.14%
-
Other operating expenses
-
-
-
-
Net income
-35.52 ሚ
-36.08 ሚ
-44.90 ሚ
-40.62 ሚ
Net profit margin
-301.29%
-165.45%
-413.44%
-400.97%
Earnings per share
-1.87
-1.29
-1.78
-1.21
Interest and investment income
2.82 ሚ
2.78 ሚ
4.24 ሚ
9.35 ሚ
Interest expense
-6.05 ሚ
-9.77 ሚ
-7.94 ሚ
-7.21 ሚ
Net interest expenses
-3.23 ሚ
-6.99 ሚ
-3.70 ሚ
2.14 ሚ
Depreciation and amortization charges
-
-
-
-
EBITDA
-31.34 ሚ
-18.90 ሚ
-38.11 ሚ
-41.61 ሚ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google መተግበሪያዎች